VivoSeq
Psychiatry

Attention Deficit Hyperactivity Disorder (ADHD)

0

Pipeline Programs↗

1

Active Trials↗

9

Companies Involved↗

Attention Deficit Hyperactivity Disorder (ADHD) is an early-stage landscape with 0 programs across 9 companies. The most active players are Takeda, Sumitomo Pharma America, Inc., Otsuka.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

0 programs

PreclinicalSumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.

0 programs

PreclinicalOtsuka logo

Otsuka

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalN

New River Pharmaceuticals

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

18

clinical trials

Completed14 · 78%
Withdrawn1 · 6%
Terminated1 · 6%
Unknown status1 · 6%
Recruiting1 · 6%

Clinical Trials

Trial Activity

18 trials

Randomised, Placebo-controlled Pilot Study to Assess the Effects of Probiotics on the Gut-brain Axis in Children With Attention Deficit Hyperactivity Disorder
Recruiting·PProbi AB·Preclinical·NCT07459699·80 enrolled
Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults
Completed·GSK logoGSK·Phase 3·NCT00048360·162 enrolled
A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)
Completed·BBioLite, Inc.·Phase 2·NCT02699086·6 enrolled
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Completed·Sumitomo Pharma America, Inc. logoSumitomo Pharma America, Inc.·Phase 3·NCT02734693·132 enrolled
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Completed·NNew River Pharmaceuticals·Phase 3·NCT00334880·420 enrolled
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Completed·Takeda logoTakeda·Phase 3·NCT00697515·142 enrolled
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Completed·Takeda logoTakeda·Phase 3·NCT02466425·264 enrolled
Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)
Completed·—·Phase 3·NCT00482313·30 enrolled
A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors
Completed·Johnson & Johnson logoJohnson & Johnson·N/A·NCT01624649·289 enrolled
Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Completed·Otsuka logoOtsuka·Phase 2·NCT02547428·85 enrolled
A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)
Completed·IIronshore Pharmaceuticals and Development, Inc·Phase 1/2·NCT01886469·22 enrolled
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Completed·Sumitomo Pharma America, Inc. logoSumitomo Pharma America, Inc.·Phase 3·NCT03231800·95 enrolled
Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)
Completed·Novartis logoNovartis·Phase 3·NCT00428792·150 enrolled
Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
Completed·Otsuka logoOtsuka·Phase 2·NCT04081363·13 enrolled
Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
Completed·AAlcobra Ltd.·Phase 2·NCT01243242·120 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)